Explore
Validate
Learn17952-1-AP
antibody from Proteintech Group
Targeting: CD274
B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [169]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [1]
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 17952-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#17952-1-AP, RRID:AB_10597552
- Product name
- PD-L1/CD274 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated PD-L1/CD274 antibody (Cat. #17952-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: FC, IF, IHC, IP, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Prostate fibroblasts and prostate cancer associated fibroblasts exhibit different metabolic, matrix degradation and PD-L1 expression responses to hypoxia.
PD-1/PD-L1 axis is involved in the interaction between microglial polarization and glioma.
PD-L1 knockdown suppresses vasculogenic mimicry of non-small cell lung cancer by modulating ZEB1-triggered EMT.
Light-Enhanced Hypoxia-Responsive Gene Editing for Hypoxia-Resistant Photodynamic and Immunotherapy.
Induction of Immunological Antitumor Effects by the Combination of Adenovirus-Mediated Gene Transfer of B7-1 and Anti-Programmed Cell Death-1 Antibody in a Murine Squamous Cell Carcinoma Model.
CDKL1 potentiates the antitumor efficacy of radioimmunotherapy by binding to transcription factor YBX1 and blocking PD-L1 expression in lung cancer.
FBXO22 is a potential therapeutic target for recurrent chondrosarcoma.
The Immune Checkpoint Protein PD-L1 Regulates Ciliogenesis and Hedgehog Signaling.
Combination of local radiotherapy and anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) therapy augments PD-L1 blockade-mediated anti-tumor effects in murine breast cancer model.
Immune Checkpoint-Blocking Nanocages Cross the Blood-Brain Barrier and Impede Brain Tumor Growth.
Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic T cells via degradation of PD-L1.
RCAd-LTH-shPD-L1, a double-gene recombinant oncolytic adenovirus with enhanced antitumor immunity, increases lymphocyte infiltration and reshapes the tumor microenvironment.
KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC.
Sulforaphane impaired immune checkpoint blockade therapy through activating ΔNP63α/PD-L1 axis in gastric cancer.
ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion.
Activation of STING by the novel liposomal TLC388 enhances the therapeutic response to anti-PD-1 antibodies in combination with radiotherapy.
ISG12a promotes immunotherapy of HBV-associated hepatocellular carcinoma through blocking TRIM21/AKT/β-catenin/PD-L1 axis.
A programmable targeted protein-degradation platform for versatile applications in mammalian cells and mice.
Anti-lung cancer synergy of low-dose doxorubicin and PD-L1 blocker co-delivered via mild photothermia-responsive black phosphorus.
Inhibition of PD-L1 expression in non-small cell lung cancer may reduce vasculogenic mimicry formation by inhibiting the epithelial mesenchymal transformation process.
High Infiltration of CD203c(+) Mast Cells Reflects Immunosuppression and Hinders Prognostic Benefit in Stage II-III Colorectal Cancer.
Targeting PD-1/PD-L1 inhibits rejection in a heterotopic tracheal allograft model of lung transplantation.
Design, Synthesis, and Activity Evaluation of Novel Dual-Target Inhibitors with Antifungal and Immunoregulatory Properties.
Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy.
Tumor cell-induced platelet aggregation accelerates hematogenous metastasis of malignant melanoma by triggering macrophage recruitment.
Evodiamine impairs HIF1A histone lactylation to inhibit Sema3A-mediated angiogenesis and PD-L1 by inducing ferroptosis in prostate cancer.
In vivo transfection of cytokine genes into tumor cells using a synthetic vehicle promotes antitumor immune responses in a visceral tumor model.
Anti-tumor effect of PD-L1-targeting antagonistic aptamer-ASO delivery system with dual inhibitory function in immunotherapy.
Exosomal PD‑L1 promotes the formation of an immunosuppressive microenvironment in gastric diffuse large B‑cell lymphoma.
The Role of Hedgehog Signaling in the Melanoma Tumor Bone Microenvironment.
Targeting HMGA1 contributes to immunotherapy in aggressive breast cancer while suppressing EMT.
BiTE-Secreting CAR-γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors.
USP51/PD-L1/ITGB1-deployed juxtacrine interaction plays a cell-intrinsic role in promoting chemoresistant phenotypes in non-small cell lung cancer.
The role of TOP2A in immunotherapy and vasculogenic mimicry in non-small cell lung cancer and its potential mechanism.
Exosomal PIK3CB promotes PD-L1 expression and malignant transformation in esophageal squamous cell carcinoma.
Fusobacterium nucleatum stimulates cell proliferation and promotes PD-L1 expression via IFIT1-related signal in colorectal cancer.
Copper transporter gene ATP7A: A predictive biomarker for immunotherapy and targeted therapy in hepatocellular carcinoma.
PD-1/PD-L1 blockade is a potent adjuvant in treatment of Staphylococcus aureus osteomyelitis in mice.
Exosomal PD-L1 confers chemoresistance and promotes tumorigenic properties in esophageal cancer cells via upregulating STAT3/miR-21.
Isothiocyanates attenuate immune checkpoint blockage therapy in gastric cancer via induction of PD-L1 expression.
Docosahexaenoic acid reverses PD-L1-mediated immune suppression by accelerating its ubiquitin-proteasome degradation.
Helicobacter pylori CagA promotes immune evasion of gastric cancer by upregulating PD-L1 level in exosomes.
YAP/STAT3 inhibited CD8(+) T cells activity in the breast cancer immune microenvironment by inducing M2 polarization of tumor-associated macrophages.
Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors.
A membrane-associated MHC-I inhibitory axis for cancer immune evasion.
Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy.
MCT4/Lactate Promotes PD-L1 Glycosylation in Triple-Negative Breast Cancer Cells.
miR-4759 suppresses breast cancer through immune checkpoint blockade.
Targeted Nanobubbles of PD-L1 mAb Combined with Doxorubicin as a Synergistic Tumor Repressor in Hepatocarcinoma.
Bifidobacterium infantis Promotes Foxp3 Expression in Colon Cells via PD-L1-Mediated Inhibition of the PI3K-Akt-mTOR Signaling Pathway.
Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells.
Ubiquitin ligase RNF125 targets PD-L1 for ubiquitination and degradation.
Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma.
Small extracellular vesicles derived from PD-L1-modified mesenchymal stem cell promote Tregs differentiation and prolong allograft survival.
STING mediates nuclear PD-L1 targeting-induced senescence in cancer cells.
A single-beam of light priming the immune responses and boosting cancer photoimmunotherapy.
Angiotensin-converting enzyme 2 identifies immuno-hot tumors suggesting angiotensin-(1-7) as a sensitizer for chemotherapy and immunotherapy in breast cancer.
Blocking PD-L1-PD-1 improves senescence surveillance and ageing phenotypes.
Biomimetic cell membrane-coated glucose/oxygen-exhausting nanoreactor for remodeling tumor microenvironment in targeted hypoxic tumor therapy.
PTX3 mediates the infiltration, migration, and inflammation-resolving-polarization of macrophages in glioblastoma.
DDR1 functions as an immune negative factor in colorectal cancer by regulating tumor-infiltrating T cells through IL-18.
Traditional Chinese medicine CFF-1 exerts a potent anti-tumor immunity to hinder tumor growth and metastasis in prostate cancer through EGFR/JAK1/STAT3 pathway to inhibit PD-1/PD-L1 checkpoint signaling.
The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment.
The IFNγ-PDL1 Pathway Enhances CD8T-DCT Interaction to Promote Hypertension.
In situ injectable hydrogel-loaded drugs induce anti-tumor immune responses in melanoma immunochemotherapy.
Whole-body PET tracking of a d-dodecapeptide and its radiotheranostic potential for PD-L1 overexpressing tumors.
eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
Ag nanoparticles enhance immune checkpoint blockade efficacy by promoting of immune surveillance in melanoma.
Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade.
Bifidobacterium infantis regulates the programmed cell death 1 pathway and immune response in mice with inflammatory bowel disease.
High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
Programmed death-ligand 1 signaling and expression are reversible by lycopene via PI3K/AKT and Raf/MEK/ERK pathways in tongue squamous cell carcinoma.
Exosome-transmitted S100A4 induces immunosuppression and non-small cell lung cancer development by activating STAT3.
Modulating Lysine Crotonylation in Cardiomyocytes Improves Myocardial Outcomes.
Piperlongumine, a piper alkaloid, enhances the efficacy of doxorubicin in breast cancer: involvement of glucose import, ROS, NF-κB and lncRNAs.
Antimelanoma Effects of Concomitant Inhibition of SIRT1 and SIRT3 in Braf(V600E)/Pten(NULL) Mice.
PD-1 inhibitor causes pathological injury to multiple organs in a Lewis lung cancer mouse model.
Syngeneically transplanted insulin producing cells differentiated from adipose derived stem cells undergo delayed damage by autoimmune responses in NOD mice.
Nanoparticle-Mediated Delivery of 2-Deoxy-D-Glucose Induces Antitumor Immunity and Cytotoxicity in Liver Tumors in Mice.
Generation of triacyl lipopeptide-modified glycoproteins by metabolic glycoengineering as the neoantigen to boost anti-tumor immune response.
Activity of the growth hormone-releasing hormone antagonist MIA602 and its underlying mechanisms of action in sarcoidosis-like granuloma.
PDIA6 promotes pancreatic cancer progression and immune escape through CSN5-mediated deubiquitination of β-catenin and PD-L1.
Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells.
TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity.
Helicobacter pylori infection disturbs the tumor immune microenvironment and is associated with a discrepant prognosis in gastric de novo diffuse large B-cell lymphoma.
Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1.
Mild hyperthermia promotes immune checkpoint blockade-based immunotherapy against metastatic pancreatic cancer using size-adjustable nanoparticles.
PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression.
Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression.
PD-L1 expression and patient outcomes in gastrointestinal neuroendocrine neoplasm: a meta-analysis.
Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer.
Anticancer nanocage platforms for combined immunotherapy designed to harness immune checkpoints and deliver anticancer drugs.
Epithelial Mutant p53 Promotes Resistance to Anti-PD-1-Mediated Oral Cancer Immunoprevention in Carcinogen-Induced Mouse Models.
WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression.
CXCL6 fuels the growth and metastases of esophageal squamous cell carcinoma cells both in vitro and in vivo through upregulation of PD-L1 via activation of STAT3 pathway.
Inhibition of NF-κB is required for oleanolic acid to downregulate PD-L1 by promoting DNA demethylation in gastric cancer cells.
Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity.
ZG16 regulates PD-L1 expression and promotes local immunity in colon cancer.
THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy.
Helicobacter urease suppresses cytotoxic CD8+ T-cell responses through activating Myh9-dependent induction of PD-L1.
KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway.
Enhanced response to PD-L1 silencing by modulation of TME via balancing glucose metabolism and robust co-delivery of siRNA/Resveratrol with dual-responsive polyplexes.
Oxymatrine reduces expression of programmed death-ligand 1 by promoting DNA demethylation in colorectal cancer cells.
Alpha-Fetoprotein Regulates the Expression of Immune-Related Proteins through the NF-κB (P65) Pathway in Hepatocellular Carcinoma Cells.
Ethyl Acetate Fraction from Hedyotis diffusa plus Scutellaria barbata Exerts Anti-Breast Cancer Effect via miR-200c-PDE7B/PD-L1-AKT/MAPK Axis.
PD-L1 and miR-34a are Prognostic Factors for Primary Gastric Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP.
CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma.
Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis.
Hepatic Artery Embolization Enhances Expression of Programmed Cell Death 1 Ligand 1 in an Orthotopic Rat Hepatocellular Carcinoma Model: In Vivo and in Vitro Experimentation.
Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas.
Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
LKB1 inhibits intrahepatic cholangiocarcinoma by repressing the transcriptional activity of the immune checkpoint PD-L1.
IL-20 antagonist suppresses PD-L1 expression and prolongs survival in pancreatic cancer models.
MiR-34a suppresses the proliferation and invasion of gastric cancer by modulating PDL1 in the immune microenvironment.
Adipose Tissue From Type 1 Diabetes Mellitus Patients Can Be Used to Generate Insulin-Producing Cells.
Epoxyazadiradione exhibit activities in head and neck squamous cell carcinoma by targeting multiple pathways.
Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression.
The innate immune effector ISG12a promotes cancer immunity by suppressing the canonical Wnt/β-catenin signaling pathway.
Lactobacillus Attenuate the Progression of Pancreatic Cancer Promoted by Porphyromonas Gingivalis in K-ras(G12D) Transgenic Mice.
BGC823 Cell Line with the Stable Expression of iRFP720 Retains Its Primary Properties with Promising Fluorescence Imaging Ability.
Differentiation of cancer cells upregulates HLA‑G and PD‑L1.
Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
PD-L1 gene promoter methylation represents a potential diagnostic marker in advanced gastric cancer.
MicroRNA‑487b‑3p inhibits osteosarcoma chemoresistance and metastasis by targeting ALDH1A3.
The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer.
Anti-inflammatory effects of α-MSH through p-CREB expression in sarcoidosis like granuloma model.
The Novel Combination of Nitroxoline and PD-1 Blockade, Exerts a Potent Antitumor Effect in a Mouse Model of Prostate Cancer.
Mycobacterium abscessus-Bronchial Epithelial Cells Cross-Talk Through Type I Interferon Signaling.
Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1.
TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1.
Vaccine against gastrin, a polyclonal antibody stimulator, decreases pancreatic cancer metastases.
Bifidobacterium infantis Induces Protective Colonic PD-L1 and Foxp3 Regulatory T Cells in an Acute Murine Experimental Model of Inflammatory Bowel Disease.
Aberrant PD-1 ligand expression contributes to the myocardial inflammatory injury caused by Coxsackievirus B infection.
Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity.
Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy.
Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression.
Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance.
Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours.
PD-1/PD-L1 Axis, Rather Than High-Mobility Group Alarmins or CD8+ Tumor-Infiltrating Lymphocytes, Is Associated With Survival in Head and Neck Squamous Cell Carcinoma Patients Who Received Surgical Resection.
Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer.
A Novel 3D in Vitro Tumor Model Based on Silk Fibroin/Chitosan Scaffolds To Mimic the Tumor Microenvironment.
The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Effects of three-dimensional collagen scaffolds on the expression profiles and biological functions of glioma cells.
[Small interfering RNA-mediated programmed cell death-ligand 1 silencing in human glioma cells enhances human CD8(+) T lymphocyte cytotoxicity in vitro].
MicroRNA-140 suppresses osteosarcoma tumor growth by enhancing anti-tumor immune response and blocking mTOR signaling.
Bone marrow mesenchymal stromal cells attenuate liver allograft rejection may via upregulation PD-L1 expression through downregulation of miR-17-5p.
Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer.
Expression of TLR4 in Non-Small Cell Lung Cancer Is Associated with PD-L1 and Poor Prognosis in Patients Receiving Pulmonectomy.
Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer.
Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma.
A Trp53fl/flPtenfl/fl mouse model of undifferentiated pleomorphic sarcoma mediated by adeno-Cre injection and in vivo bioluminescence imaging.
Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients.
miR-217 inhibits laryngeal cancer metastasis by repressing AEG-1 and PD-L1 expression.
PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways.
High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers.
miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity.
Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.
PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions.
Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer.
WITHDRAWN: Prognostic Significance of Programmed Cell Death-Ligand 1 Expression in Patients With Resected Lung Adenocarcinoma.
The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures.
High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma.
Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models.
Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Immunological markers predict the prognosis of patients with squamous non-small cell lung cancer.
Assessing the Effects of Concurrent versus Sequential Cisplatin/Radiotherapy on Immune Status in Lung Tumor-Bearing C57BL/6 Mice.
Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis.
Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma.
Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.
Pacheco-Torres J, Sharma RK, Mironchik Y, Wildes F, Brennen WN, Artemov D, Krishnamachary B, Bhujwalla ZM
Frontiers in molecular biosciences 2024;11:1354076
Frontiers in molecular biosciences 2024;11:1354076
PD-1/PD-L1 axis is involved in the interaction between microglial polarization and glioma.
Wang XP, Guo W, Chen YF, Hong C, Ji J, Zhang XY, Dong YF, Sun XL
International immunopharmacology 2024 May 30;133:112074
International immunopharmacology 2024 May 30;133:112074
PD-L1 knockdown suppresses vasculogenic mimicry of non-small cell lung cancer by modulating ZEB1-triggered EMT.
Li W, Wu J, Jia Q, Shi Y, Li F, Zhang L, Shi F, Wang X, Wu S
BMC cancer 2024 May 23;24(1):633
BMC cancer 2024 May 23;24(1):633
Light-Enhanced Hypoxia-Responsive Gene Editing for Hypoxia-Resistant Photodynamic and Immunotherapy.
Qu S, Ji Y, Fan L, Yan T, Zhu G, Song H, Yang K, Han X
Advanced healthcare materials 2024 Mar;13(7):e2302615
Advanced healthcare materials 2024 Mar;13(7):e2302615
Induction of Immunological Antitumor Effects by the Combination of Adenovirus-Mediated Gene Transfer of B7-1 and Anti-Programmed Cell Death-1 Antibody in a Murine Squamous Cell Carcinoma Model.
Hara M, Saburi S, Uehara N, Tsujikawa T, Kubo M, Furukawa T, Teshima M, Shinomiya H, Hirano S, Nibu KI
Cancers 2024 Mar 30;16(7)
Cancers 2024 Mar 30;16(7)
CDKL1 potentiates the antitumor efficacy of radioimmunotherapy by binding to transcription factor YBX1 and blocking PD-L1 expression in lung cancer.
Li Z, Xue H, Li J, Zheng Z, Liu Z, Dong X, Wang H, Chen J, Xu S
Journal of experimental & clinical cancer research : CR 2024 Mar 22;43(1):89
Journal of experimental & clinical cancer research : CR 2024 Mar 22;43(1):89
FBXO22 is a potential therapeutic target for recurrent chondrosarcoma.
Xin B, Chen H, Zhu Z, Guan Q, Bai G, Yang C, Zou W, Gao X, Li L, Liu T
Journal of bone oncology 2024 Jun;46:100605
Journal of bone oncology 2024 Jun;46:100605
The Immune Checkpoint Protein PD-L1 Regulates Ciliogenesis and Hedgehog Signaling.
Agborbesong E, Li X
Cells 2024 Jun 8;13(12)
Cells 2024 Jun 8;13(12)
Combination of local radiotherapy and anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) therapy augments PD-L1 blockade-mediated anti-tumor effects in murine breast cancer model.
Song JY, Han MG, Kim Y, Kim MJ, Kang MH, Jeon SH, Kim IA
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2024 Jan;190:109981
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2024 Jan;190:109981
Immune Checkpoint-Blocking Nanocages Cross the Blood-Brain Barrier and Impede Brain Tumor Growth.
Kim M, Yoon HJ, Lee C, Lee M, Park RW, Lee B, Park EJ, Kim S
ACS biomaterials science & engineering 2024 Jan 8;10(1):575-587
ACS biomaterials science & engineering 2024 Jan 8;10(1):575-587
Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic T cells via degradation of PD-L1.
Ren W, Xu Z, Chang Y, Ju F, Wu H, Liang Z, Zhao M, Wang N, Lin Y, Xu C, Chen S, Rao Y, Lin C, Yang J, Liu P, Zhang J, Huang C, Xia N
Nature communications 2024 Jan 2;15(1):9
Nature communications 2024 Jan 2;15(1):9
RCAd-LTH-shPD-L1, a double-gene recombinant oncolytic adenovirus with enhanced antitumor immunity, increases lymphocyte infiltration and reshapes the tumor microenvironment.
Meng Y, Liu H, Zhu H, Zhang W, Sun D, Han X, Liu Y, Luo G
Journal for immunotherapy of cancer 2024 Jan 11;12(1)
Journal for immunotherapy of cancer 2024 Jan 11;12(1)
KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC.
Li J, Shi D, Li S, Shi X, Liu Y, Zhang Y, Wang G, Zhang C, Xia T, Piao HL, Liu HX
Cell death & disease 2024 Feb 27;15(2):175
Cell death & disease 2024 Feb 27;15(2):175
Sulforaphane impaired immune checkpoint blockade therapy through activating ΔNP63α/PD-L1 axis in gastric cancer.
Zhang Q, Yang C, Ma Z, Ye L, Wu Y, Zhong C, Shi Y, Zhu M
Molecular carcinogenesis 2024 Aug;63(8):1611-1620
Molecular carcinogenesis 2024 Aug;63(8):1611-1620
ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion.
Deng S, Zhang Y, Wang H, Liang W, Xie L, Li N, Fang Y, Wang Y, Liu J, Chi H, Sun Y, Ye R, Shan L, Shi J, Shen Z, Wang Y, Wang S, Brosseau JP, Wang F, Liu G, Quan Y, Xu J
Cell 2024 Apr 25;187(9):2305-2323.e33
Cell 2024 Apr 25;187(9):2305-2323.e33
Activation of STING by the novel liposomal TLC388 enhances the therapeutic response to anti-PD-1 antibodies in combination with radiotherapy.
Chen JY, Lin PY, Hong WZ, Yang PC, Chiang SF, Chang HY, Ke TW, Liang JA, Chen WT, Chao KSC, Huang KC
Cancer immunology, immunotherapy : CII 2024 Apr 2;73(5):92
Cancer immunology, immunotherapy : CII 2024 Apr 2;73(5):92
ISG12a promotes immunotherapy of HBV-associated hepatocellular carcinoma through blocking TRIM21/AKT/β-catenin/PD-L1 axis.
Deng R, Tian R, Li X, Xu Y, Li Y, Wang X, Li H, Wang L, Xu B, Yang D, Tang S, Xue B, Zuo C, Zhu H
iScience 2024 Apr 19;27(4):109533
iScience 2024 Apr 19;27(4):109533
A programmable targeted protein-degradation platform for versatile applications in mammalian cells and mice.
Ma X, Yin J, Qiao L, Wan H, Liu X, Zhou Y, Wu J, Niu L, Wu M, Wang X, Ye H
Molecular cell 2024 Apr 18;84(8):1585-1600.e7
Molecular cell 2024 Apr 18;84(8):1585-1600.e7
Anti-lung cancer synergy of low-dose doxorubicin and PD-L1 blocker co-delivered via mild photothermia-responsive black phosphorus.
Xu HZ, Chen FX, Li K, Zhang Q, Han N, Li TF, Xu YH, Chen Y, Chen X
Drug delivery and translational research 2024 Apr 10;
Drug delivery and translational research 2024 Apr 10;
Inhibition of PD-L1 expression in non-small cell lung cancer may reduce vasculogenic mimicry formation by inhibiting the epithelial mesenchymal transformation process.
Shi Y, Li W, Jia Q, Wu J, Wu S, Wu S
Experimental cell research 2024 Apr 1;437(1):113996
Experimental cell research 2024 Apr 1;437(1):113996
High Infiltration of CD203c(+) Mast Cells Reflects Immunosuppression and Hinders Prognostic Benefit in Stage II-III Colorectal Cancer.
Li J, Mo Y, Wei Q, Chen J, Xu G
Journal of inflammation research 2023;16:723-735
Journal of inflammation research 2023;16:723-735
Targeting PD-1/PD-L1 inhibits rejection in a heterotopic tracheal allograft model of lung transplantation.
Kaiho T, Suzuki H, Hata A, Matsumoto H, Tanaka K, Sakairi Y, Motohashi S, Yoshino I
Frontiers in pharmacology 2023;14:1298085
Frontiers in pharmacology 2023;14:1298085
Design, Synthesis, and Activity Evaluation of Novel Dual-Target Inhibitors with Antifungal and Immunoregulatory Properties.
Sun B, Liu W, Wang Q, Liu Y, Yu S, Liu M, Han J
Journal of medicinal chemistry 2023 Sep 28;66(18):13007-13027
Journal of medicinal chemistry 2023 Sep 28;66(18):13007-13027
Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy.
Sun K, Zhang X, Lao M, He L, Wang S, Yang H, Xu J, Tang J, Hong Z, Song J, Guo C, Li M, Liu X, Chen Y, Zhang H, Zhou J, Lin J, Zhang S, Hong Y, Huang J, Liang T, Bai X
Molecular therapy : the journal of the American Society of Gene Therapy 2023 Oct 4;31(10):2929-2947
Molecular therapy : the journal of the American Society of Gene Therapy 2023 Oct 4;31(10):2929-2947
Tumor cell-induced platelet aggregation accelerates hematogenous metastasis of malignant melanoma by triggering macrophage recruitment.
Chen Y, Zhou J, Liu Z, Wu T, Li S, Zhang Y, Yin X, Yang G, Zhang G
Journal of experimental & clinical cancer research : CR 2023 Oct 23;42(1):277
Journal of experimental & clinical cancer research : CR 2023 Oct 23;42(1):277
Evodiamine impairs HIF1A histone lactylation to inhibit Sema3A-mediated angiogenesis and PD-L1 by inducing ferroptosis in prostate cancer.
Yu Y, Huang X, Liang C, Zhang P
European journal of pharmacology 2023 Oct 15;957:176007
European journal of pharmacology 2023 Oct 15;957:176007
In vivo transfection of cytokine genes into tumor cells using a synthetic vehicle promotes antitumor immune responses in a visceral tumor model.
Watanabe S, Takagi A, Yuba E, Kojima C, Dei N, Matsumoto A, Tanikawa J, Kawamura T, De Silva NH, Izawa T, Akazawa T, Kanegi R, Hatoya S, Inaba T, Sugiura K
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2023 Nov;37(11):e23228
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2023 Nov;37(11):e23228
Anti-tumor effect of PD-L1-targeting antagonistic aptamer-ASO delivery system with dual inhibitory function in immunotherapy.
Luo F, Yang G, Bai X, Yuan D, Li L, Wang D, Lu X, Cheng Y, Wang Y, Song X, Zhao Y
Cell chemical biology 2023 Nov 16;30(11):1390-1401.e6
Cell chemical biology 2023 Nov 16;30(11):1390-1401.e6
Exosomal PD‑L1 promotes the formation of an immunosuppressive microenvironment in gastric diffuse large B‑cell lymphoma.
Zeng H, Wang J, Xu B, Deng H, Peng M, Deng R, Shang S, Hu Q, Li J, Lin J, Zhu H, Li Y, Zuo C
Oncology reports 2023 May;49(5)
Oncology reports 2023 May;49(5)
The Role of Hedgehog Signaling in the Melanoma Tumor Bone Microenvironment.
Shamsoon K, Hiraki D, Yoshida K, Takabatake K, Takebe H, Yokozeki K, Horie N, Fujita N, Nasrun NE, Okui T, Nagatsuka H, Abiko Y, Hosoya A, Saito T, Shimo T
International journal of molecular sciences 2023 May 16;24(10)
International journal of molecular sciences 2023 May 16;24(10)
Targeting HMGA1 contributes to immunotherapy in aggressive breast cancer while suppressing EMT.
Chang X, Liu J, Yang Q, Gao Y, Ding X, Zhao J, Li Y, Liu Z, Li Z, Wu Y, Zuo D
Biochemical pharmacology 2023 Jun;212:115582
Biochemical pharmacology 2023 Jun;212:115582
BiTE-Secreting CAR-γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors.
Huang SW, Pan CM, Lin YC, Chen MC, Chen Y, Jan CI, Wu CC, Lin FY, Wang ST, Lin CY, Lin PY, Huang WH, Chiang YT, Tsai WC, Chiu YH, Lin TH, Chiu SC, Cho DY
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2023 Jun;10(17):e2206856
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2023 Jun;10(17):e2206856
USP51/PD-L1/ITGB1-deployed juxtacrine interaction plays a cell-intrinsic role in promoting chemoresistant phenotypes in non-small cell lung cancer.
Li J, Xiao X, Ou Y, Cao L, Guo M, Qi C, Wang Z, Liu Y, Shuai Q, Wang H, Sun P, Shi Y, Yang G, Yang S
Cancer communications (London, England) 2023 Jul;43(7):765-787
Cancer communications (London, England) 2023 Jul;43(7):765-787
The role of TOP2A in immunotherapy and vasculogenic mimicry in non-small cell lung cancer and its potential mechanism.
Wu J, Zhang L, Li W, Wang L, Jia Q, Shi F, Li K, Liao L, Shi Y, Wu S
Scientific reports 2023 Jul 5;13(1):10906
Scientific reports 2023 Jul 5;13(1):10906
Exosomal PIK3CB promotes PD-L1 expression and malignant transformation in esophageal squamous cell carcinoma.
Xu W, Chen Y, Zhang Z, Jiang Y, Wang Z
Medical oncology (Northwood, London, England) 2023 Jul 4;40(8):221
Medical oncology (Northwood, London, England) 2023 Jul 4;40(8):221
Fusobacterium nucleatum stimulates cell proliferation and promotes PD-L1 expression via IFIT1-related signal in colorectal cancer.
Gao Y, Zou T, Xu P, Wang Y, Jiang Y, Chen YX, Chen H, Hong J, Fang JY
Neoplasia (New York, N.Y.) 2023 Jan;35:100850
Neoplasia (New York, N.Y.) 2023 Jan;35:100850
Copper transporter gene ATP7A: A predictive biomarker for immunotherapy and targeted therapy in hepatocellular carcinoma.
Shao K, Shen H, Chen X, Shao Z, Liu Y, Wang Y, Chen H, Wu X
International immunopharmacology 2023 Jan;114:109518
International immunopharmacology 2023 Jan;114:109518
PD-1/PD-L1 blockade is a potent adjuvant in treatment of Staphylococcus aureus osteomyelitis in mice.
Li K, Chen Y, Lin Y, Zhang G, Su J, Wu X, Cheng C, Wang Y, Yu B, Zhang X
Molecular therapy : the journal of the American Society of Gene Therapy 2023 Jan 4;31(1):174-192
Molecular therapy : the journal of the American Society of Gene Therapy 2023 Jan 4;31(1):174-192
Exosomal PD-L1 confers chemoresistance and promotes tumorigenic properties in esophageal cancer cells via upregulating STAT3/miR-21.
Wang H, Qi Y, Lan Z, Liu Q, Xu J, Zhu M, Yang T, Shi R, Gao S, Liang G
Gene therapy 2023 Feb;30(1-2):88-100
Gene therapy 2023 Feb;30(1-2):88-100
Isothiocyanates attenuate immune checkpoint blockage therapy in gastric cancer via induction of PD-L1 expression.
Zhang Q, Cao W, Yang C, Hong L, Geng S, Han H, Zhong C
The Journal of nutritional biochemistry 2023 Feb;112:109226
The Journal of nutritional biochemistry 2023 Feb;112:109226
Docosahexaenoic acid reverses PD-L1-mediated immune suppression by accelerating its ubiquitin-proteasome degradation.
Zhang H, Chen H, Yin S, Fan L, Jin C, Zhao C, Hu H
The Journal of nutritional biochemistry 2023 Feb;112:109186
The Journal of nutritional biochemistry 2023 Feb;112:109186
Helicobacter pylori CagA promotes immune evasion of gastric cancer by upregulating PD-L1 level in exosomes.
Wang J, Deng R, Chen S, Deng S, Hu Q, Xu B, Li J, He Z, Peng M, Lei S, Ma T, Chen Z, Zhu H, Zuo C
iScience 2023 Dec 15;26(12):108414
iScience 2023 Dec 15;26(12):108414
YAP/STAT3 inhibited CD8(+) T cells activity in the breast cancer immune microenvironment by inducing M2 polarization of tumor-associated macrophages.
Wang C, Shen N, Guo Q, Tan X, He S
Cancer medicine 2023 Aug;12(15):16295-16309
Cancer medicine 2023 Aug;12(15):16295-16309
Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors.
Zhang L, Zhang S, Wu J, Wang Y, Wu Y, Sun X, Wang X, Shen J, Xie L, Zhang Y, Zhang H, Hu K, Wang F, Wang R, Zhang MR
Molecular pharmaceutics 2023 Aug 7;20(8):4256-4267
Molecular pharmaceutics 2023 Aug 7;20(8):4256-4267
A membrane-associated MHC-I inhibitory axis for cancer immune evasion.
Chen X, Lu Q, Zhou H, Liu J, Nadorp B, Lasry A, Sun Z, Lai B, Rona G, Zhang J, Cammer M, Wang K, Al-Santli W, Ciantra Z, Guo Q, You J, Sengupta D, Boukhris A, Zhang H, Liu C, Cresswell P, Dahia PLM, Pagano M, Aifantis I, Wang J
Cell 2023 Aug 31;186(18):3903-3920.e21
Cell 2023 Aug 31;186(18):3903-3920.e21
Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy.
Lee CK, Atibalentja DF, Yao LE, Park J, Kuruvilla S, Felsher DW
Nanotheranostics 2022;6(3):243-255
Nanotheranostics 2022;6(3):243-255
MCT4/Lactate Promotes PD-L1 Glycosylation in Triple-Negative Breast Cancer Cells.
Duan X, Xie Y, Yu J, Hu X, Liu Z, Li N, Qin J, Lan L, Yuan M, Pan Z, Wang Y
Journal of oncology 2022;2022:3659714
Journal of oncology 2022;2022:3659714
miR-4759 suppresses breast cancer through immune checkpoint blockade.
Lin YZ, Liu SH, Wu WR, Shen YC, Wang YL, Liao CC, Lin PL, Chang H, Liu LC, Cheng WC, Wang SC
Computational and structural biotechnology journal 2022;20:241-251
Computational and structural biotechnology journal 2022;20:241-251
Targeted Nanobubbles of PD-L1 mAb Combined with Doxorubicin as a Synergistic Tumor Repressor in Hepatocarcinoma.
Chen Y, Luo X, Liu Y, Zou Y, Yang S, Liu C, Zhao Y
International journal of nanomedicine 2022;17:3989-4008
International journal of nanomedicine 2022;17:3989-4008
Bifidobacterium infantis Promotes Foxp3 Expression in Colon Cells via PD-L1-Mediated Inhibition of the PI3K-Akt-mTOR Signaling Pathway.
Zhou L, Xie Y, Li Y
Frontiers in immunology 2022;13:871705
Frontiers in immunology 2022;13:871705
Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells.
Tu J, Xu H, Ma L, Li C, Qin W, Chen X, Yi M, Sun L, Liu B, Yuan X
Theranostics 2022;12(2):747-766
Theranostics 2022;12(2):747-766
Ubiquitin ligase RNF125 targets PD-L1 for ubiquitination and degradation.
Wei M, Mo Y, Liu J, Zhai J, Li H, Xu Y, Peng Y, Tang Z, Wei T, Yang X, Huang L, Shao X, Li J, Zhou L, Zhong H, Wei C, Xie Q, Min M, Wu F
Frontiers in oncology 2022;12:835603
Frontiers in oncology 2022;12:835603
Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma.
Liu Z, Zhou K, Zeng J, Zhou X, Li H, Peng K, Liu X, Li F, Jiang B, Zhao M, Ma T
Oncology reports 2022 Sep;48(3)
Oncology reports 2022 Sep;48(3)
Small extracellular vesicles derived from PD-L1-modified mesenchymal stem cell promote Tregs differentiation and prolong allograft survival.
Ou Q, Dou X, Tang J, Wu P, Pan D
Cell and tissue research 2022 Sep;389(3):465-481
Cell and tissue research 2022 Sep;389(3):465-481
STING mediates nuclear PD-L1 targeting-induced senescence in cancer cells.
Lee JJ, Kim SY, Kim SH, Choi S, Lee B, Shin JS
Cell death & disease 2022 Sep 15;13(9):791
Cell death & disease 2022 Sep 15;13(9):791
A single-beam of light priming the immune responses and boosting cancer photoimmunotherapy.
Sun Y, Han R, Wang J, Qin Y, Ren Z, Feng X, Liu Q, Wang X
Journal of controlled release : official journal of the Controlled Release Society 2022 Oct;350:734-747
Journal of controlled release : official journal of the Controlled Release Society 2022 Oct;350:734-747
Angiotensin-converting enzyme 2 identifies immuno-hot tumors suggesting angiotensin-(1-7) as a sensitizer for chemotherapy and immunotherapy in breast cancer.
Mei J, Cai Y, Xu R, Yu X, Han X, Weng M, Chen L, Ma T, Gao T, Gao F, Xia T, Zhu Y, Zhang Y
Biological procedures online 2022 Oct 25;24(1):15
Biological procedures online 2022 Oct 25;24(1):15
Blocking PD-L1-PD-1 improves senescence surveillance and ageing phenotypes.
Wang TW, Johmura Y, Suzuki N, Omori S, Migita T, Yamaguchi K, Hatakeyama S, Yamazaki S, Shimizu E, Imoto S, Furukawa Y, Yoshimura A, Nakanishi M
Nature 2022 Nov;611(7935):358-364
Nature 2022 Nov;611(7935):358-364
Biomimetic cell membrane-coated glucose/oxygen-exhausting nanoreactor for remodeling tumor microenvironment in targeted hypoxic tumor therapy.
Guo H, Zhang W, Wang L, Shao Z, Huang X
Biomaterials 2022 Nov;290:121821
Biomaterials 2022 Nov;290:121821
PTX3 mediates the infiltration, migration, and inflammation-resolving-polarization of macrophages in glioblastoma.
Zhang H, Wang Y, Zhao Y, Liu T, Wang Z, Zhang N, Dai Z, Wu W, Cao H, Feng S, Zhang L, Cheng Q, Liu Z
CNS neuroscience & therapeutics 2022 Nov;28(11):1748-1766
CNS neuroscience & therapeutics 2022 Nov;28(11):1748-1766
DDR1 functions as an immune negative factor in colorectal cancer by regulating tumor-infiltrating T cells through IL-18.
Duan X, Xu X, Zhang Y, Gao Y, Zhou J, Li J
Cancer science 2022 Nov;113(11):3672-3685
Cancer science 2022 Nov;113(11):3672-3685
Traditional Chinese medicine CFF-1 exerts a potent anti-tumor immunity to hinder tumor growth and metastasis in prostate cancer through EGFR/JAK1/STAT3 pathway to inhibit PD-1/PD-L1 checkpoint signaling.
Zhang Y, Wei Y, Jiang S, Dang Y, Yang Y, Zuo W, Zhu Q, Liu P, Gao Y, Lu S
Phytomedicine : international journal of phytotherapy and phytopharmacology 2022 May;99:153939
Phytomedicine : international journal of phytotherapy and phytopharmacology 2022 May;99:153939
The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment.
Zhang P, Qin C, Liu N, Zhou X, Chu X, Lv F, Gu Y, Yin L, Liu J, Zhou J, Huo M
Biomaterials 2022 May;284:121518
Biomaterials 2022 May;284:121518
The IFNγ-PDL1 Pathway Enhances CD8T-DCT Interaction to Promote Hypertension.
Benson LN, Liu Y, Wang X, Xiong Y, Rhee SW, Guo Y, Deck KS, Mora CJ, Li LX, Huang L, Andrews JT, Qin Z, Hoover RS, Ko B, Williams RM, Heller DA, Jaimes EA, Mu S
Circulation research 2022 May 13;130(10):1550-1564
Circulation research 2022 May 13;130(10):1550-1564
In situ injectable hydrogel-loaded drugs induce anti-tumor immune responses in melanoma immunochemotherapy.
Li J, Luo G, Zhang C, Long S, Guo L, Yang G, Wang F, Zhang L, Shi L, Fu Y, Zhang Y
Materials today. Bio 2022 Mar;14:100238
Materials today. Bio 2022 Mar;14:100238
Whole-body PET tracking of a d-dodecapeptide and its radiotheranostic potential for PD-L1 overexpressing tumors.
Hu K, Wu W, Xie L, Geng H, Zhang Y, Hanyu M, Zhang L, Liu Y, Nagatsu K, Suzuki H, Guo J, Wu Y, Li Z, Wang F, Zhang M
Acta pharmaceutica Sinica. B 2022 Mar;12(3):1363-1376
Acta pharmaceutica Sinica. B 2022 Mar;12(3):1363-1376
eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
Chen X, Wang K, Jiang S, Sun H, Che X, Zhang M, He J, Wen Y, Liao M, Li X, Zhou X, Song J, Ren X, Yi W, Yang J, Chen X, Yin M, Cheng Y
Journal for immunotherapy of cancer 2022 Mar;10(3)
Journal for immunotherapy of cancer 2022 Mar;10(3)
Ag nanoparticles enhance immune checkpoint blockade efficacy by promoting of immune surveillance in melanoma.
Kuang X, Wang Z, Luo Z, He Z, Liang L, Gao Q, Li Y, Xia K, Xie Z, Chang R, Wang Y, Liu Y, Zhao S, Su J, Wang Y, Situ W, Chen M, Zhao Y, Chen X, Xie H, Liu H
Journal of colloid and interface science 2022 Jun 15;616:189-200
Journal of colloid and interface science 2022 Jun 15;616:189-200
Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade.
Kawada-Horitani E, Kita S, Okita T, Nakamura Y, Nishida H, Honma Y, Fukuda S, Tsugawa-Shimizu Y, Kozawa J, Sakaue T, Kawachi Y, Fujishima Y, Nishizawa H, Azuma M, Maeda N, Shimomura I
Diabetologia 2022 Jul;65(7):1185-1197
Diabetologia 2022 Jul;65(7):1185-1197
Bifidobacterium infantis regulates the programmed cell death 1 pathway and immune response in mice with inflammatory bowel disease.
Zhou LY, Xie Y, Li Y
World journal of gastroenterology 2022 Jul 14;28(26):3164-3176
World journal of gastroenterology 2022 Jul 14;28(26):3164-3176
High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
Chen X, Kong H, Luo L, Han S, Lei T, Yu H, Guo N, Li C, Peng S, Dong X, Yang H, Wu M
BMC cancer 2022 Jan 3;22(1):9
BMC cancer 2022 Jan 3;22(1):9
Programmed death-ligand 1 signaling and expression are reversible by lycopene via PI3K/AKT and Raf/MEK/ERK pathways in tongue squamous cell carcinoma.
Peng M, Fan S, Li J, Zhou X, Liao Q, Tang F, Liu W
Genes & nutrition 2022 Feb 14;17(1):3
Genes & nutrition 2022 Feb 14;17(1):3
Exosome-transmitted S100A4 induces immunosuppression and non-small cell lung cancer development by activating STAT3.
Wu X, Zhang H, Jiang G, Peng M, Li C, Lu J, Jiang S, Yang X, Jiang Y
Clinical and experimental immunology 2022 Dec 31;210(3):309-320
Clinical and experimental immunology 2022 Dec 31;210(3):309-320
Modulating Lysine Crotonylation in Cardiomyocytes Improves Myocardial Outcomes.
Cai W, Xu D, Zeng C, Liao F, Li R, Lin Y, Zhao Y, Dong W, Wang Q, Yang H, Wen D, Gu J, Shentu W, Yu H, Zhang X, Wei J, Duan J
Circulation research 2022 Aug 19;131(5):456-472
Circulation research 2022 Aug 19;131(5):456-472
Piperlongumine, a piper alkaloid, enhances the efficacy of doxorubicin in breast cancer: involvement of glucose import, ROS, NF-κB and lncRNAs.
Awasthee N, Shekher A, Rai V, Verma SS, Mishra S, Dhasmana A, Gupta SC
Apoptosis : an international journal on programmed cell death 2022 Apr;27(3-4):261-282
Apoptosis : an international journal on programmed cell death 2022 Apr;27(3-4):261-282
Antimelanoma Effects of Concomitant Inhibition of SIRT1 and SIRT3 in Braf(V600E)/Pten(NULL) Mice.
Chhabra G, Singh CK, Guzmán-Pérez G, Ndiaye MA, Iczkowski KA, Ahmad N
The Journal of investigative dermatology 2022 Apr;142(4):1145-1157.e7
The Journal of investigative dermatology 2022 Apr;142(4):1145-1157.e7
PD-1 inhibitor causes pathological injury to multiple organs in a Lewis lung cancer mouse model.
Chen Y, Liu Y, Xiong X, Zeng Z, Luo D, Liu A
International immunopharmacology 2022 Apr;105:108551
International immunopharmacology 2022 Apr;105:108551
Syngeneically transplanted insulin producing cells differentiated from adipose derived stem cells undergo delayed damage by autoimmune responses in NOD mice.
Tokuda K, Ikemoto T, Yamashita S, Miyazaki K, Okikawa S, Yamada S, Saito Y, Morine Y, Shimada M
Scientific reports 2022 Apr 7;12(1):5852
Scientific reports 2022 Apr 7;12(1):5852
Nanoparticle-Mediated Delivery of 2-Deoxy-D-Glucose Induces Antitumor Immunity and Cytotoxicity in Liver Tumors in Mice.
Sasaki K, Nishina S, Yamauchi A, Fukuda K, Hara Y, Yamamura M, Egashira K, Hino K
Cellular and molecular gastroenterology and hepatology 2021;11(3):739-762
Cellular and molecular gastroenterology and hepatology 2021;11(3):739-762
Generation of triacyl lipopeptide-modified glycoproteins by metabolic glycoengineering as the neoantigen to boost anti-tumor immune response.
Zhao Y, Li S, Lv J, Liu Y, Chen Y, Liu Y, Chen X, Li J, Qin X, Wang X, Shi J, Shi Y, Xiang R
Theranostics 2021;11(15):7425-7438
Theranostics 2021;11(15):7425-7438
Activity of the growth hormone-releasing hormone antagonist MIA602 and its underlying mechanisms of action in sarcoidosis-like granuloma.
Zhang C, Tian R, Dreifus EM, Hashemi Shahraki A, Holt G, Cai R, Griswold A, Bejarano P, Jackson R, V Schally A, Mirsaeidi M
Clinical & translational immunology 2021;10(7):e1310
Clinical & translational immunology 2021;10(7):e1310
PDIA6 promotes pancreatic cancer progression and immune escape through CSN5-mediated deubiquitination of β-catenin and PD-L1.
Ma Y, Xia P, Wang Z, Xu J, Zhang L, Jiang Y
Neoplasia (New York, N.Y.) 2021 Sep;23(9):912-928
Neoplasia (New York, N.Y.) 2021 Sep;23(9):912-928
Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells.
Xu HZ, Li TF, Wang C, Ma Y, Liu Y, Zheng MY, Liu ZJ, Chen JB, Li K, Sun SK, Komatsu N, Xu YH, Zhao L, Chen X
Journal of nanobiotechnology 2021 Sep 6;19(1):268
Journal of nanobiotechnology 2021 Sep 6;19(1):268
TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity.
Ren Y, Qian Y, Ai L, Xie Y, Gao Y, Zhuang Z, Chen J, Chen YX, Fang JY
Nature communications 2021 Sep 13;12(1):5405
Nature communications 2021 Sep 13;12(1):5405
Helicobacter pylori infection disturbs the tumor immune microenvironment and is associated with a discrepant prognosis in gastric de novo diffuse large B-cell lymphoma.
Deng Y, Su W, Zhu J, Ji H, Zhou X, Geng J, Zhu J, Zhang Q
Journal for immunotherapy of cancer 2021 Oct;9(10)
Journal for immunotherapy of cancer 2021 Oct;9(10)
Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1.
Tian W, Sun Y, Cheng Y, Ma X, Du W, Shi W, Guo Q
Thoracic cancer 2021 Oct;12(19):2551-2563
Thoracic cancer 2021 Oct;12(19):2551-2563
Mild hyperthermia promotes immune checkpoint blockade-based immunotherapy against metastatic pancreatic cancer using size-adjustable nanoparticles.
Yu Q, Tang X, Zhao W, Qiu Y, He J, Wan D, Li J, Wang X, He X, Liu Y, Li M, Zhang Z, He Q
Acta biomaterialia 2021 Oct 1;133:244-256
Acta biomaterialia 2021 Oct 1;133:244-256
PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression.
Wu L, Cai S, Deng Y, Zhang Z, Zhou X, Su Y, Xu D
International immunopharmacology 2021 May;94:107443
International immunopharmacology 2021 May;94:107443
Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression.
Zhang H, Xia Y, Wang F, Luo M, Yang K, Liang S, An S, Wu S, Yang C, Chen D, Xu M, Cai M, To KKW, Fu L
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2021 May;8(10):2003404
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2021 May;8(10):2003404
PD-L1 expression and patient outcomes in gastrointestinal neuroendocrine neoplasm: a meta-analysis.
Lee W, Kim MJ, Choi Y, Kim H
Translational cancer research 2021 May;10(5):2210-2218
Translational cancer research 2021 May;10(5):2210-2218
Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer.
Al-Badran SS, Grant L, Campo MV, Inthagard J, Pennel K, Quinn J, Konanahalli P, Hayman L, Horgan PG, McMillan DC, Roxburgh CS, Roseweir A, Park JH, Edwards J
The journal of pathology. Clinical research 2021 Mar;7(2):121-134
The journal of pathology. Clinical research 2021 Mar;7(2):121-134
Anticancer nanocage platforms for combined immunotherapy designed to harness immune checkpoints and deliver anticancer drugs.
Jeon IS, Yoo JD, Gurung S, Kim M, Lee C, Park EJ, Park RW, Lee B, Kim S
Biomaterials 2021 Mar;270:120685
Biomaterials 2021 Mar;270:120685
Epithelial Mutant p53 Promotes Resistance to Anti-PD-1-Mediated Oral Cancer Immunoprevention in Carcinogen-Induced Mouse Models.
Wang J, Hu Y, Escamilla-Rivera V, Gonzalez CL, Tang L, Wang B, El-Naggar AK, Myers JN, Caulin C
Cancers 2021 Mar 23;13(6)
Cancers 2021 Mar 23;13(6)
WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression.
Wu M, Xia X, Hu J, Fowlkes NW, Li S
Nature communications 2021 Jun 9;12(1):3500
Nature communications 2021 Jun 9;12(1):3500
CXCL6 fuels the growth and metastases of esophageal squamous cell carcinoma cells both in vitro and in vivo through upregulation of PD-L1 via activation of STAT3 pathway.
Zheng S, Shen T, Liu Q, Liu T, Tuerxun A, Zhang Q, Yang L, Han X, Lu X
Journal of cellular physiology 2021 Jul;236(7):5373-5386
Journal of cellular physiology 2021 Jul;236(7):5373-5386
Inhibition of NF-κB is required for oleanolic acid to downregulate PD-L1 by promoting DNA demethylation in gastric cancer cells.
Lu X, Li Y, Yang W, Tao M, Dai Y, Xu J, Xu Q
Journal of biochemical and molecular toxicology 2021 Jan;35(1):e22621
Journal of biochemical and molecular toxicology 2021 Jan;35(1):e22621
Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity.
Li C, Yao H, Wang H, Fang JY, Xu J
Oncogene 2021 Feb;40(6):1128-1146
Oncogene 2021 Feb;40(6):1128-1146
ZG16 regulates PD-L1 expression and promotes local immunity in colon cancer.
Meng H, Ding Y, Liu E, Li W, Wang L
Translational oncology 2021 Feb;14(2):101003
Translational oncology 2021 Feb;14(2):101003
THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy.
Li C, Chi H, Deng S, Wang H, Yao H, Wang Y, Chen D, Guo X, Fang JY, He F, Xu J
Journal for immunotherapy of cancer 2021 Aug;9(8)
Journal for immunotherapy of cancer 2021 Aug;9(8)
Helicobacter urease suppresses cytotoxic CD8+ T-cell responses through activating Myh9-dependent induction of PD-L1.
Wu J, Zhu X, Guo X, Yang Z, Cai Q, Gu D, Luo W, Yuan C, Xiang Y
International immunology 2021 Aug 23;33(9):491-504
International immunology 2021 Aug 23;33(9):491-504
KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway.
Du W, Zhu J, Zeng Y, Liu T, Zhang Y, Cai T, Fu Y, Zhang W, Zhang R, Liu Z, Huang JA
Cell death and differentiation 2021 Apr;28(4):1284-1300
Cell death and differentiation 2021 Apr;28(4):1284-1300
Enhanced response to PD-L1 silencing by modulation of TME via balancing glucose metabolism and robust co-delivery of siRNA/Resveratrol with dual-responsive polyplexes.
Jia L, Gao Y, Zhou T, Zhao XL, Hu HY, Chen DW, Qiao MX
Biomaterials 2021 Apr;271:120711
Biomaterials 2021 Apr;271:120711
Oxymatrine reduces expression of programmed death-ligand 1 by promoting DNA demethylation in colorectal cancer cells.
Hua S, Gu M, Wang Y, Ban D, Ji H
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2021 Apr;23(4):750-756
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2021 Apr;23(4):750-756
Alpha-Fetoprotein Regulates the Expression of Immune-Related Proteins through the NF-κB (P65) Pathway in Hepatocellular Carcinoma Cells.
Li QT, Qiu MJ, Yang SL, Fang X, He XX, Wang MM, Li YN, Xiong ZF, Huang S
Journal of oncology 2020;2020:9327512
Journal of oncology 2020;2020:9327512
Ethyl Acetate Fraction from Hedyotis diffusa plus Scutellaria barbata Exerts Anti-Breast Cancer Effect via miR-200c-PDE7B/PD-L1-AKT/MAPK Axis.
Yang Y, Fang T, Cao YL, Lv YX, Chang QQ, Zhang DD
Evidence-based complementary and alternative medicine : eCAM 2020;2020:3587095
Evidence-based complementary and alternative medicine : eCAM 2020;2020:3587095
PD-L1 and miR-34a are Prognostic Factors for Primary Gastric Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP.
Wang J, Shang S, Li J, Deng H, Ouyang L, Xie H, Zhu H, Li Y, Zuo C
Cancer management and research 2020;12:4999-5008
Cancer management and research 2020;12:4999-5008
CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma.
Song Y, Song W, Li Z, Song W, Wen Y, Li J, Xia Q, Zhang M
Frontiers in oncology 2020;10:488
Frontiers in oncology 2020;10:488
Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis.
Cai H, Zhang H, Jiang Y
Frontiers in oncology 2020;10:1079
Frontiers in oncology 2020;10:1079
Hepatic Artery Embolization Enhances Expression of Programmed Cell Death 1 Ligand 1 in an Orthotopic Rat Hepatocellular Carcinoma Model: In Vivo and in Vitro Experimentation.
Takaki H, Hirata Y, Ueshima E, Kodama H, Matsumoto S, Wada R, Suzuki H, Nakasho K, Yamakado K
Journal of vascular and interventional radiology : JVIR 2020 Sep;31(9):1475-1482.e2
Journal of vascular and interventional radiology : JVIR 2020 Sep;31(9):1475-1482.e2
Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas.
Yoon CJ, Chang MS, Kim DH, Kim W, Koo BK, Yun SC, Kim SH, Kim YS, Woo JH
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2020 Sep;23(5):780-795
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2020 Sep;23(5):780-795
Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S, Passariello M, Agnello L, Esposito S, Collina F, Cantile M, Di Bonito M, Ulasov IV, Fedele M, Zannetti A, De Lorenzo C, Cerchia L
Journal of experimental & clinical cancer research : CR 2020 Sep 7;39(1):180
Journal of experimental & clinical cancer research : CR 2020 Sep 7;39(1):180
LKB1 inhibits intrahepatic cholangiocarcinoma by repressing the transcriptional activity of the immune checkpoint PD-L1.
Liu Z, Li S, Zeng J, Zhou X, Li H, Liu X, Li F, Jiang B, Zhao M, Ma T
Life sciences 2020 Sep 15;257:118068
Life sciences 2020 Sep 15;257:118068
IL-20 antagonist suppresses PD-L1 expression and prolongs survival in pancreatic cancer models.
Lu SW, Pan HC, Hsu YH, Chang KC, Wu LW, Chen WY, Chang MS
Nature communications 2020 Sep 14;11(1):4611
Nature communications 2020 Sep 14;11(1):4611
MiR-34a suppresses the proliferation and invasion of gastric cancer by modulating PDL1 in the immune microenvironment.
Yong H, Fu J, Gao G, Shi H, Zheng D, Zhou X
Molecular and cellular probes 2020 Oct;53:101601
Molecular and cellular probes 2020 Oct;53:101601
Adipose Tissue From Type 1 Diabetes Mellitus Patients Can Be Used to Generate Insulin-Producing Cells.
Ikemoto T, Tokuda K, Wada Y, Gao L, Miyazaki K, Yamada S, Saito Y, Imura S, Morine Y, Shimada M
Pancreas 2020 Oct;49(9):1225-1231
Pancreas 2020 Oct;49(9):1225-1231
Epoxyazadiradione exhibit activities in head and neck squamous cell carcinoma by targeting multiple pathways.
Rai V, Aggarwal SK, Verma SS, Awasthee N, Dhasmana A, Aggarwal S, Das SN, Nair MS, Yadav S, Gupta SC
Apoptosis : an international journal on programmed cell death 2020 Oct;25(9-10):763-782
Apoptosis : an international journal on programmed cell death 2020 Oct;25(9-10):763-782
Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression.
Cai X, Wei B, Li L, Chen X, Liu W, Cui J, Lin Y, Sun Y, Xu Q, Guo W, Gu Y
International immunopharmacology 2020 Nov;88:106858
International immunopharmacology 2020 Nov;88:106858
The innate immune effector ISG12a promotes cancer immunity by suppressing the canonical Wnt/β-catenin signaling pathway.
Deng R, Zuo C, Li Y, Xue B, Xun Z, Guo Y, Wang X, Xu Y, Tian R, Chen S, Liu Q, Chen J, Wang J, Huang X, Li H, Guo M, Wang X, Yang M, Wu Z, Wang J, Ma J, Hu J, Li G, Tang S, Tu Z, Ji H, Zhu H
Cellular & molecular immunology 2020 Nov;17(11):1163-1179
Cellular & molecular immunology 2020 Nov;17(11):1163-1179
Lactobacillus Attenuate the Progression of Pancreatic Cancer Promoted by Porphyromonas Gingivalis in K-ras(G12D) Transgenic Mice.
Chen SM, Hsu LJ, Lee HL, Lin CP, Huang SW, Lai CJ, Lin CW, Chen WT, Chen YJ, Lin YC, Yang CC, Jan MS
Cancers 2020 Nov 26;12(12)
Cancers 2020 Nov 26;12(12)
BGC823 Cell Line with the Stable Expression of iRFP720 Retains Its Primary Properties with Promising Fluorescence Imaging Ability.
Hu H, Zhang Z, Wang R, Wang Y, Jin J, Cai L, Yang J, Duan H, Wu Z, Fang Z, Liu B
DNA and cell biology 2020 May;39(5):900-908
DNA and cell biology 2020 May;39(5):900-908
Differentiation of cancer cells upregulates HLA‑G and PD‑L1.
Ullah M, Meziani S, Shah S, Kaci R, Pimpie C, Pocard M, Mirshahi M
Oncology reports 2020 Jun;43(6):1797-1804
Oncology reports 2020 Jun;43(6):1797-1804
Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
Choi E, Chang MS, Byeon SJ, Jin H, Jung KC, Kim H, Lee KL, Kim W, Park JH, Kim KH, Kim JS, Choi IS, Han DS, Ahn HS, Heo SC
Diagnostic pathology 2020 Jun 4;15(1):69
Diagnostic pathology 2020 Jun 4;15(1):69
PD-L1 gene promoter methylation represents a potential diagnostic marker in advanced gastric cancer.
Lv D, Xing C, Cao L, Zhuo Y, Wu T, Gao N
Oncology letters 2020 Feb;19(2):1223-1234
Oncology letters 2020 Feb;19(2):1223-1234
MicroRNA‑487b‑3p inhibits osteosarcoma chemoresistance and metastasis by targeting ALDH1A3.
Cheng M, Duan PG, Gao ZZ, Dai M
Oncology reports 2020 Dec;44(6):2691-2700
Oncology reports 2020 Dec;44(6):2691-2700
The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer.
Chen TC, Wu CT, Wang CP, Lou PJ, Ko JY, Chang YL
Oral oncology 2020 Dec;111:104945
Oral oncology 2020 Dec;111:104945
Anti-inflammatory effects of α-MSH through p-CREB expression in sarcoidosis like granuloma model.
Zhang C, Chery S, Lazerson A, Altman NH, Jackson R, Holt G, Campos M, Schally AV, Mirsaeidi M
Scientific reports 2020 Apr 29;10(1):7277
Scientific reports 2020 Apr 29;10(1):7277
The Novel Combination of Nitroxoline and PD-1 Blockade, Exerts a Potent Antitumor Effect in a Mouse Model of Prostate Cancer.
Xu N, Huang L, Li X, Watanabe M, Li C, Xu A, Liu C, Li Q, Araki M, Wada K, Nasu Y, Huang P
International journal of biological sciences 2019;15(5):919-928
International journal of biological sciences 2019;15(5):919-928
Mycobacterium abscessus-Bronchial Epithelial Cells Cross-Talk Through Type I Interferon Signaling.
Zhang C, Asif H, Holt GE, Griswold AJ, Campos M, Bejarano P, Fregien NL, Mirsaeidi M
Frontiers in immunology 2019;10:2888
Frontiers in immunology 2019;10:2888
Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1.
D'Alterio C, Buoncervello M, Ieranò C, Napolitano M, Portella L, Rea G, Barbieri A, Luciano A, Scognamiglio G, Tatangelo F, Anniciello AM, Monaco M, Cavalcanti E, Maiolino P, Romagnoli G, Arra C, Botti G, Gabriele L, Scala S
Journal of experimental & clinical cancer research : CR 2019 Oct 28;38(1):432
Journal of experimental & clinical cancer research : CR 2019 Oct 28;38(1):432
TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1.
Zhang C, Duan Y, Xia M, Dong Y, Chen Y, Zheng L, Chai S, Zhang Q, Wei Z, Liu N, Wang J, Sun C, Tang Z, Cheng X, Wu J, Wang G, Zheng F, Laurence A, Li B, Yang XP
Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Nov 15;25(22):6827-6838
Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Nov 15;25(22):6827-6838
Vaccine against gastrin, a polyclonal antibody stimulator, decreases pancreatic cancer metastases.
Osborne N, Sundseth R, Gay MD, Cao H, Tucker RD, Nadella S, Wang S, Liu X, Kroemer A, Sutton L, Cato A, Smith JP
American journal of physiology. Gastrointestinal and liver physiology 2019 Nov 1;317(5):G682-G693
American journal of physiology. Gastrointestinal and liver physiology 2019 Nov 1;317(5):G682-G693
Bifidobacterium infantis Induces Protective Colonic PD-L1 and Foxp3 Regulatory T Cells in an Acute Murine Experimental Model of Inflammatory Bowel Disease.
Zhou L, Liu D, Xie Y, Yao X, Li Y
Gut and liver 2019 Mar 15;13(4):430-439
Gut and liver 2019 Mar 15;13(4):430-439
Aberrant PD-1 ligand expression contributes to the myocardial inflammatory injury caused by Coxsackievirus B infection.
Wang T, Chen S, Wang X, Huang Y, Qiu J, Fei Y, Chaulagain A, Chen Y, Wang Y, Lin L, Yan B, Wang Y, Wang W, Zhao W, Zhong Z
Antiviral research 2019 Jun;166:1-10
Antiviral research 2019 Jun;166:1-10
Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity.
Tao Z, Ruan H, Sun L, Kuang D, Song Y, Wang Q, Wang T, Hao Y, Chen K
Cancer immunology research 2019 Jul;7(7):1135-1147
Cancer immunology research 2019 Jul;7(7):1135-1147
Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy.
Wan WJ, Qu CX, Zhou YJ, Zhang L, Chen MT, Liu Y, You BG, Li F, Wang DD, Zhang XN
International journal of pharmaceutics 2019 Jul 20;566:731-744
International journal of pharmaceutics 2019 Jul 20;566:731-744
Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression.
Jin X, Ding D, Yan Y, Li H, Wang B, Ma L, Ye Z, Ma T, Wu Q, Rodrigues DN, Kohli M, Jimenez R, Wang L, Goodrich DW, de Bono J, Dong H, Wu H, Zhu R, Huang H
Molecular cell 2019 Jan 3;73(1):22-35.e6
Molecular cell 2019 Jan 3;73(1):22-35.e6
Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance.
Chen SW, Li SH, Shi DB, Jiang WM, Song M, Yang AK, Li YD, Bei JX, Chen WK, Zhang Q
The International journal of biological markers 2019 Dec;34(4):398-405
The International journal of biological markers 2019 Dec;34(4):398-405
Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours.
Yao H, Lan J, Li C, Shi H, Brosseau JP, Wang H, Lu H, Fang C, Zhang Y, Liang L, Zhou X, Wang C, Xue Y, Cui Y, Xu J
Nature biomedical engineering 2019 Apr;3(4):306-317
Nature biomedical engineering 2019 Apr;3(4):306-317
PD-1/PD-L1 Axis, Rather Than High-Mobility Group Alarmins or CD8+ Tumor-Infiltrating Lymphocytes, Is Associated With Survival in Head and Neck Squamous Cell Carcinoma Patients Who Received Surgical Resection.
Yang F, Zeng Z, Li J, Zheng Y, Wei F, Ren X
Frontiers in oncology 2018;8:604
Frontiers in oncology 2018;8:604
Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer.
Dong P, Xiong Y, Yu J, Chen L, Tao T, Yi S, Hanley SJB, Yue J, Watari H, Sakuragi N
Oncogene 2018 Sep;37(39):5257-5268
Oncogene 2018 Sep;37(39):5257-5268
A Novel 3D in Vitro Tumor Model Based on Silk Fibroin/Chitosan Scaffolds To Mimic the Tumor Microenvironment.
Li J, Zhou Y, Chen W, Yuan Z, You B, Liu Y, Yang S, Li F, Qu C, Zhang X
ACS applied materials & interfaces 2018 Oct 31;10(43):36641-36651
ACS applied materials & interfaces 2018 Oct 31;10(43):36641-36651
The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K, Toyokawa G, Shoji F, Okamoto T, Maehara Y
Clinical lung cancer 2018 Mar;19(2):120-129
Clinical lung cancer 2018 Mar;19(2):120-129
Effects of three-dimensional collagen scaffolds on the expression profiles and biological functions of glioma cells.
Jia W, Jiang X, Liu W, Wang L, Zhu B, Zhu H, Liu X, Zhong M, Xie D, Huang W, Jia W, Li S, Liu X, Zuo X, Cheng D, Dai J, Ren C
International journal of oncology 2018 Jun;52(6):1787-1800
International journal of oncology 2018 Jun;52(6):1787-1800
[Small interfering RNA-mediated programmed cell death-ligand 1 silencing in human glioma cells enhances human CD8(+) T lymphocyte cytotoxicity in vitro].
Wang Z, Huang W, Cen B, Wei Y, Liao L, Li G, Ji A
Nan fang yi ke da xue xue bao = Journal of Southern Medical University 2018 Jul 30;38(7):800-806
Nan fang yi ke da xue xue bao = Journal of Southern Medical University 2018 Jul 30;38(7):800-806
MicroRNA-140 suppresses osteosarcoma tumor growth by enhancing anti-tumor immune response and blocking mTOR signaling.
Ji X, Wang E, Tian F
Biochemical and biophysical research communications 2018 Jan 1;495(1):1342-1348
Biochemical and biophysical research communications 2018 Jan 1;495(1):1342-1348
Bone marrow mesenchymal stromal cells attenuate liver allograft rejection may via upregulation PD-L1 expression through downregulation of miR-17-5p.
Chen Q, Zhou R, Zhang Y, Zhu S, Xiao C, Gong J, Li K, Tang H, Sun C, Zhang J
Transplant immunology 2018 Dec;51:21-29
Transplant immunology 2018 Dec;51:21-29
Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer.
Meder L, Schuldt P, Thelen M, Schmitt A, Dietlein F, Klein S, Borchmann S, Wennhold K, Vlasic I, Oberbeck S, Riedel R, Florin A, Golfmann K, Schlößer HA, Odenthal M, Buettner R, Wolf J, Hallek M, Herling M, von Bergwelt-Baildon M, Reinhardt HC, Ullrich RT
Cancer research 2018 Aug 1;78(15):4270-4281
Cancer research 2018 Aug 1;78(15):4270-4281
Expression of TLR4 in Non-Small Cell Lung Cancer Is Associated with PD-L1 and Poor Prognosis in Patients Receiving Pulmonectomy.
Wang K, Wang J, Wei F, Zhao N, Yang F, Ren X
Frontiers in immunology 2017;8:456
Frontiers in immunology 2017;8:456
Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer.
Kumar S, Davra V, Obr AE, Geng K, Wood TL, De Lorenzo MS, Birge RB
Oncoimmunology 2017;7(1):e1376155
Oncoimmunology 2017;7(1):e1376155
Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma.
Kikuchi M, Clump DA, Srivastava RM, Sun L, Zeng D, Diaz-Perez JA, Anderson CJ, Edwards WB, Ferris RL
Oncoimmunology 2017;6(7):e1329071
Oncoimmunology 2017;6(7):e1329071
A Trp53fl/flPtenfl/fl mouse model of undifferentiated pleomorphic sarcoma mediated by adeno-Cre injection and in vivo bioluminescence imaging.
Buchakjian MR, Merritt NM, Moose DL, Dupuy AJ, Tanas MR, Henry MD
PloS one 2017;12(8):e0183469
PloS one 2017;12(8):e0183469
Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients.
Chen J, Li H, Pang R, Huang J
OncoTargets and therapy 2017;10:2003-2007
OncoTargets and therapy 2017;10:2003-2007
miR-217 inhibits laryngeal cancer metastasis by repressing AEG-1 and PD-L1 expression.
Miao S, Mao X, Zhao S, Song K, Xiang C, Lv Y, Jiang H, Wang L, Li B, Yang X, Yuan Z, Xiu C, Meng H, Sun J
Oncotarget 2017 Sep 22;8(37):62143-62153
Oncotarget 2017 Sep 22;8(37):62143-62153
PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways.
Liu S, Chen S, Yuan W, Wang H, Chen K, Li D, Li D
Oncotarget 2017 Nov 21;8(59):99901-99912
Oncotarget 2017 Nov 21;8(59):99901-99912
High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers.
Chang YL, Yang CY, Huang YL, Wu CT, Yang PC
Oncotarget 2017 Mar 14;8(11):18021-18030
Oncotarget 2017 Mar 14;8(11):18021-18030
miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity.
Jia L, Xi Q, Wang H, Zhang Z, Liu H, Cheng Y, Guo X, Zhang J, Zhang Q, Zhang L, Xue Z, Li Y, Da Y, Zhao P, Zhang R
Biochemical and biophysical research communications 2017 Jun 24;488(2):425-431
Biochemical and biophysical research communications 2017 Jun 24;488(2):425-431
Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.
Kim KJ, Kim JH, Lee SJ, Lee EJ, Shin EC, Seong J
Oncotarget 2017 Jun 20;8(25):41242-41255
Oncotarget 2017 Jun 20;8(25):41242-41255
PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions.
Wang J, Xie T, Wang B, William WN Jr, Heymach JV, El-Naggar AK, Myers JN, Caulin C
Cancer prevention research (Philadelphia, Pa.) 2017 Dec;10(12):684-693
Cancer prevention research (Philadelphia, Pa.) 2017 Dec;10(12):684-693
Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer.
Yang CY, Lin MW, Chang YL, Wu CT
Cancer biomarkers : section A of Disease markers 2017 Dec 12;21(1):211-220
Cancer biomarkers : section A of Disease markers 2017 Dec 12;21(1):211-220
WITHDRAWN: Prognostic Significance of Programmed Cell Death-Ligand 1 Expression in Patients With Resected Lung Adenocarcinoma.
Hung JJ, Huang SF, Shen YY, Wu YC, Chou TY, Hsu WH
The Annals of thoracic surgery 2016 Oct 13;
The Annals of thoracic surgery 2016 Oct 13;
The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures.
Lin Z, Xu Y, Zhang Y, He Q, Zhang J, He J, Liang W
Oncotarget 2016 Mar 22;7(12):15033-46
Oncotarget 2016 Mar 22;7(12):15033-46
High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma.
Chang YL, Yang CY, Lin MW, Wu CT, Yang PC
European journal of cancer (Oxford, England : 1990) 2016 Jun;60:125-35
European journal of cancer (Oxford, England : 1990) 2016 Jun;60:125-35
Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models.
Lanzel EA, Paula Gomez Hernandez M, Bates AM, Treinen CN, Starman EE, Fischer CL, Parashar D, Guthmiller JM, Johnson GK, Abbasi T, Vali S, Brogden KA
Cancer immunology, immunotherapy : CII 2016 Dec;65(12):1511-1522
Cancer immunology, immunotherapy : CII 2016 Dec;65(12):1511-1522
Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Yang CY, Lin MW, Chang YL, Wu CT, Yang PC
European journal of cancer (Oxford, England : 1990) 2016 Apr;57:91-103
European journal of cancer (Oxford, England : 1990) 2016 Apr;57:91-103
Immunological markers predict the prognosis of patients with squamous non-small cell lung cancer.
Jiang L, Zhao Z, Jiang S, Lin Y, Yang H, Xie Z, Lin Y, Long H
Immunologic research 2015 Jul;62(3):316-24
Immunologic research 2015 Jul;62(3):316-24
Assessing the Effects of Concurrent versus Sequential Cisplatin/Radiotherapy on Immune Status in Lung Tumor-Bearing C57BL/6 Mice.
Kao CJ, Wurz GT, Lin YC, Vang DP, Griffey SM, Wolf M, DeGregorio MW
Cancer immunology research 2015 Jul;3(7):741-50
Cancer immunology research 2015 Jul;3(7):741-50
Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis.
Zhang Y, Kang S, Shen J, He J, Jiang L, Wang W, Guo Z, Peng G, Chen G, He J, Liang W
Medicine 2015 Feb;94(6):e515
Medicine 2015 Feb;94(6):e515
Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma.
Han L, Liu F, Li R, Li Z, Chen X, Zhou Z, Zhang X, Hu T, Zhang Y, Young K, Sun S, Wen J, Zhang M
Oncology letters 2014 Oct;8(4):1461-1469
Oncology letters 2014 Oct;8(4):1461-1469
Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.
Yang CY, Lin MW, Chang YL, Wu CT, Yang PC
European journal of cancer (Oxford, England : 1990) 2014 May;50(7):1361-9
European journal of cancer (Oxford, England : 1990) 2014 May;50(7):1361-9
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- mouse heart tissue were subjected to SDS PAGE followed by western blot with 17952-1-AP( PD-L1/CD274 Antibody) at dilution of 1:300
- Sample type
- tissue
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The PD-L1/CD274 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human PD-L1/CD274. This antibody recognizes human,mouse,rat antigen. The PD-L1/CD274 antibody has been validated for the following applications: ELISA, IHC, WB, IF analysis.
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human heart using 17952-1-AP(PD-L1 antibody) at dilution of 1:100 (under 10x lens)
- Sample type
- tissue
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human heart using 17952-1-AP(PD-L1 antibody) at dilution of 1:100 (under 40x lens)
- Sample type
- tissue
